Both Wegovy and Mounjaro are clinically proven weight-loss injections available on private prescription in Ireland. Our consultant specialist explains the differences.
GLP-1 Weight Loss Treatment
Wegovy (semaglutide) and Mounjaro (tirzepatide) are both injectable GLP-1 receptor agonists approved for chronic weight management and available on private prescription in Ireland.
| Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| Average weight loss | ~15% body weight (STEP trials) | ~20-22% body weight (SURMOUNT trials) |
| Injection frequency | Once weekly | Once weekly |
| Cardiovascular benefit | Proven vs placebo (SELECT trial) - 20% CVD risk reduction | Non-inferior to dulaglutide on MACE (SURPASS-CVOT, published NEJM); not a placebo-controlled outcome trial |
| Side effects | Nausea, vomiting, diarrhoea, constipation | Nausea, diarrhoea, vomiting, constipation |
| Starting dose | 0.25mg/week, escalate to 2.4mg/week | 2.5mg/week, escalate to 15mg/week |
A higher 7.2 mg once-weekly Wegovy dose was approved by the European Commission in February 2026 (Phase 3b STEP UP trial), but is not yet available for prescribing in Ireland.
Wegovy (Semaglutide)
The SELECT cardiovascular outcome trial (2023, NEJM) showed a 20% reduction in major cardiovascular events in people with obesity who had pre-existing heart disease. Wegovy is the first anti-obesity drug proven to reduce heart attacks and strokes.
Mounjaro (Tirzepatide)
Tirzepatide (Mounjaro) acts on two hormone receptors - GLP-1 and GIP. The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose. Excellent for patients with type 2 diabetes or insulin resistance.
FAQ
Yes. At Naas Cardiology & Endocrinology Clinic, Dr Kazmi accepts self-referrals. A full medical history review including blood tests is required before prescribing.
Most patients notice appetite reduction within 1-2 weeks. Meaningful weight loss (5-10%) typically occurs within 3 months. Maximum effect at 12-16 months on maintenance dose.
Yes. Some patients switch from Wegovy to Mounjaro if they plateau, or vice versa. This transition is managed by your consultant with an appropriate washout period if required.
Start Your Treatment
Dr Kazmi, Consultant Endocrinologist (IMC 213626). Saturday & Sunday appointments in Naas, Co. Kildare.
Wegovy (semaglutide) has proven cardiovascular benefits and is preferred for patients with existing heart disease. Mounjaro (tirzepatide) produces greater average weight loss (~20%) and is better for type 2 diabetes or insulin resistance. A specialist consultation is essential to determine which is right for you.
Yes. Dr Kazmi (Consultant Endocrinologist, IMC 213626) at Naas Cardiology & Endocrinology Clinic accepts self-referrals. Saturday & Sunday clinics in Naas, Co. Kildare. Call 089 656 7597.